Ciclosporin for Rheumatology and Dermatology use (Adults)
|
|
- Kelly Bates
- 5 years ago
- Views:
Transcription
1 Shared Care Guideline Ciclosporin for Rheumatology and Dermatology use (Adults) Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing the prescribing of ciclosporin for indications listed below. Indication Rheumatic and connective tissue disease Severe psoriasis in patients in whom conventional therapy is inappropriate or ineffective. Other cutaneous disease Dosage and administration Indications not covered by this shared care guideline: Prevention of graft rejection (see separate shared care guideline from tertiary centre). Endogenous uveitis Nephrotic syndrome For ALL indications patients should remain on the brand initiated and prescribing should be brand specific. Rheumatic and connective tissue disease Initiated at 1-2mg/kg day orally in two divided doses for six weeks (as per the Yorkshire DMARD guidelines).then increase every two weeks by incremental doses of 25mg until clinically effective. Maximum dose should not exceed 4mg/kg/day. If after 3 months of treatment at the maximum permitted or tolerable dose the response is considered inadequate treatment should be discontinued. For maintenance treatment the dose has to be titrated individually according to tolerability. Cutaneous disease The usual dose is 2.5-5mg/kg in 2 divided doses. The daily dose is usually gradually increased but should not exceed 5mg/kg/day. Initial doses of 5mg/kg per day are justified in patients whose condition requires rapid improvement. Administration Ciclosporin should be taken twice daily, every twelve hours. The 100mg capsule is large and patients may prefer to take the 50mg strength. The oral solution (Neoral brand) can be mixed with orange juice (or squash) or apple juice to improve taste, or mixed with water immediately before taking. Rinse the container with juice or water to ensure the total dose is taken. Do not mix with grapefruit juice. The measuring syringe should not be rinsed with water, alcohol or any other liquid. If it is necessary to clean the measuring device, the outside should be wiped with a dry tissue.
2 Due to the oily component of ciclosporin (Neoral) solution adherence to enteral feeding tubes may occur resulting in subtherapeutic doses. Contraindications and cautions Adverse drug reactions Contraindications : Hypersensitivity to ciclosporin or to any of the other excipients Concomitant use of tacrolimus Concomitant use of rosuvastatin (SPC recommendation) or simvastatin (MHRA recommendation Aug 2012) Concomitant use of aliskiren, dabigatran, lercanidipine (BNF advises to avoid) Abnormal renal function Uncontrolled hypertension Infections not under control Malignancy (other than of skin when being used in dermatology) Pregnancy ciclosporin is compatible with pregnancy at the lowest effective dose and mothers should not be discouraged from breast feeding. (from new BSR guidance) Live vaccines (see interactions) For full list see SPC at Many side effects associated with ciclosporin therapy are dosedependent and responsive to dose reduction. Common Nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia, tremor, headache, paraesthesia. Hypertension Hypertension (BP >130/>80mmHg) is a commonly encountered adverse effect which the GP will be best placed to monitor and treat. Standard antihypertensives can be used but avoid diltiazem, nicardipine, felodipine and verapamil as they may increase plasma ciclosporin levels. Benign gingival hyperplasia This is relatively common with ciclosporin especially when nifedipine is co-prescribed. Patients should be advised to brush their teeth twice daily. Hirsutism Hirsutism may be a problem, particularly to dark skinned females. Facial hair bleaches and depilatory creams are safe and often effective but electrolysis should be avoided because of infection risk. Headache, tremor, and paraesthesiae These adverse effects are frequently seen. If persistent or severe, they may reflect toxic levels of ciclosporin. In this case, the patient should be referred back to the specialist. Hepatic dysfunction and hyperlipidaemia Hepatic dysfunction and hyperlipidaemia should be routinely monitored for. In the event of increased lipids being found, restriction of dietary fat and, if appropriate, a dose reduction, should be considered. Some statins are contra-indicated with ciclosporin or must be used at a lower dose (see under interactions).ciclosporin may enhance statin myopathy. Nephrotoxicity
3 An acute nephrotoxicity may occur with ciclosporin which is usually identified by serum creatinine monitoring and is reversible by dose reduction. If serum creatinine consistently >30% above patients baseline, decrease ciclosporin dose by 25-50%. A chronic nephrotoxicity may also occur requiring withdrawal of this drug. Cancer risk Like all immunosuppressant s, ciclosporin increases the risk of developing lymphomas and other malignancies, particularly those of the skin. Patients should be advised to avoid excessive exposure to the sun and use high factor sunscreens. For full list see BNF or SPC at Drug Interactions Ciclosporin is metabolised by cytochrome P450 and therefore interacts with many drugs that are also metabolised by this group of liver enzymes. The following drugs /foods increase or reduce ciclosporin levels Interacting drugs Antibiotics - Erythromycin, clarithromycin, azithromycin Calcium channel blockers - Diltiazem, nicardipine verapamil. Lercanidipine(BNF advises to avoid) Antifungals - Fluconazole, itraconazole, ketoconazole Grapefruit juice or fruit Others - metoclopramide, oral contraceptives, danazol, allopurinol, amiodarone, colchicine Rifampicin Antiepileptics Carbamazepine, phenobarbital, phenytoin Anti-obesity - Orlistat St John s Wort Other interacting agents: Effects on ciclosporin blood levels Tacrolimus contraindicated Statins Simvastatin and rosuvastatin are contra-indicated with ciclosporin Atorvastatin should be used at a maximum dose of 10mg daily in combination with ciclosporin Pravastatin can be used to a maximum dose of 40mg daily in combination with ciclosporin NSAIDs and other nephrotoxic drugs (e.g. aminoglycosides,amphotericin B, ciprofloxacin, trimethoprim, methotrexate (unless initiated by consultant team) Diclofenac see above under NSAIDS. In addition always half the dose of diclofenac when ciclosporin is co-prescribed. Potassium-sparing medicines may exacerbate ciclosporin-
4 induced hyperkalaemia and should only be initiated with regular monitoring of U&E s. Live vaccines avoid Digoxin, colchicine ciclosporin may increases levels of these drugs For full list see BNF or SPC at Duration of Treatment Responsibilities of the specialist initiating treatment Long term Dermatology patients: 6 moths to 1 year in majority of patients General: To assess the suitability of the patient for treatment. To ensure that the patient/carer has received counselling and understands the therapy, its benefits, limitations, continued monitoring (where applicable), adverse effects. Inform the GP of the information provided to the patient. To review the patient as agreed intervals and copy all relevant results to the GP Carry out disease and drug monitoring as listed below Formally hand over to GP by letter and patient informed Responsibilities of the General Prescribing: Initiate treatment with ciclosporin. The GPs will be typically asked to take up the monitoring and prescribing of ciclosporin approximately 2 months after it. has been initiated. Disease & drug monitoring: Monitor bloods according to schedule: Blood Baseline pressure Urinalysis FBC U+Es LFTS Urate and lipids 24 hour urine creatinine clearance Blood pressure U+Es FBC LFTS Lipids In Rheumatic and connective tissue disease Serum creatinine needs to be measured at least twice before commencing treatment. In cutaneous disease A dermatological and physical examination including blood pressure and renal function required before starting. Then every 2 weeks until stable dose reached for more than 6 weeks and no change in NSAID therapy (RA patients). After the first month of treatment. Discuss shared care arrangement with patient. Support and advise GPs as required. Assess response to treatment and initiate any dose changes as clinically appropriate including discontinuation of treatment. General and Prescribing: Monitor and prescribe as recommended by the specialist. The
5 Practitioner GPs will be typically asked to take up the monitoring and prescribing of ciclosporin approximately 2 months after it has been initiated or when the patient is on a stable dose. Vaccinations note annual influenza vaccine and single dose pneumococcal vaccine should be offered unless otherwise advised by the specialist. If patients are exposed to chickenpox or shingles, passive immunisation should be carried out using varicella zoster immunoglobulin. Please contact consultant microbiologist for further advice or refer to the green book (chapter 34). Notify specialist if treatment with ciclosporin is discontinued or if unable to take on shared care.. Ensure there are no drug interactions with any other medications initiated in primary care. Prescribe by brand Disease & drug monitoring: Carry out drug monitoring as listed and communicate abnormal results to the specialist. Ensure the correct brand of ciclosporin is prescribed as stated by the prescriber. Urgent drug discontinuation/ referral to specialist as clinically appropriate To stop treatment on the advice of the specialist. To refer back to the specialist if the patient s condition deteriorates. To identify adverse effects if the patient presents with any signs and liaise with the hospital specialist where necessary. To report adverse effects to the specialist and where appropriate to the Commission on Human Medicines/MHRA (Yellow Card scheme). Unless otherwise stated by the secondary care specialist, apply the following monitoring frequencies following handover from secondary care: Blood Monthly for 4 months then every 3 months. pressure U+Es FBC LFTs Lipids At consultations On dose increase at week 2,4, 8 and then every 3 months as above. Every 3 months. If no change at 6 months stop monitoring routinely Ask about oral ulceration, unexplained bruising/ bleeding, rash, sore throat. Discontinue ciclosporin and seek advice from initiating team if: WCC <3.5x10 9 /L Neutrophils <2 x 10 9 /L AST or ALT >3 times upper limit of normal Platelets <140 x10 9 /L
6 Responsibilities of the Patient / Carer: Communication Blood pressure Potassium Creatinine Lipids General : >160/95 or risen >20mmHg (despite the addition of standard antihypertensive therapy. >5.5mmol/l Rises by >30% of baseline on 2 consecutive occasions one week apart. Significant rise Report any possible side effects to their GP, in particular potential signs and symptoms of bone marrow suppression (e.g. unexplained bruising, bleeding, sore throat, infection etc.) Practice safe exposure to the sun Ensure they have adequate supply of medication. Attend appointments including those for drug monitoring. Discuss options if considering pregnancy with GP/specialist To notify the Dr issuing prescriptions (hospital or GP) if wishing to start any new medication purchased over the counter (including herbal remedies) Specialist to GP: The specialist will inform the GP when they have initiated ciclosporin and when there are any subsequent changes in treatment. Inform the GP of the information provided to the patient Ensure that brand of ciclosporin has been communicated with GP GP to Specialist: To inform specialist if not able to take on the monitoring and prescribing Irrespective of whether prescribing responsibility has been accepted or not, inform the consultant of relevant medical information regarding the patient and changes to the patient s medication regime irrespective of indication. Notify specialist if treatment with ciclosporin discontinued. Specialist Contacts Prescribing specialist to be contacted via Hospital switchboard on Medicines Information
7 References British National Formulary on line 30/09/15 Summary of Product Characteristics Accessed 30/09/15 BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Chakravarty K et al. Rheumatology Click here to access Yorkshire Regional Rheumatology DMARD Guidelines, 6 th Edition, revised May Click here to access the DMARD Guidelines
ORAL CICLOSPORIN RHEUMATOLOGY LOCAL SAFETY MONITORING SCHEDULE
ORAL CICLOSPORIN RHEUMATOLOGY LOCAL SAFETY MONITORING SCHEDULE This local safety-monitoring schedule supports clinicians under the Local Enhanced Service for High Risk Drug Monitoring (formerly Near Patient
More informationTacrolimus (Adoport, Prograf, Modigraf or Advagraf )
Shared Care Guideline DRUG: Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) for Renal Transplant (Adults) Introduction: Indication: Prophylaxis of transplant rejection in kidney recipients Tacrolimus
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationPrescribing Framework for Ciclosporin Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Ciclosporin Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationShared Care Protocol Responsibilities
Oxfordshire Clinical Commissioning Group CICLOSPORIN FOR USE IN DERMATOLOGY, RHEUMATOLOGY, NEUROLOGY and GASTROENTEROLOGY Shared Care Protocol This protocol provides prescribing and monitoring guidance
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: CICLOSPORIN INDICATION/S COVERED: FOR RHEUMATOLOGY AND DERMATOLOGY Coastal West Sussex Traffic Light system classification: Amber N.B. The eligibility
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationPlease complete all sections 1. Name of Drug, Brand Name, Form and Strength
GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline Ciclosporin for use in childhood nephrotic syndrome Reference Number Replaces: n/a Issue date: 15/10/2015 Author(s)/Originator(s):
More informationEffective Shared Care Agreement (ESCA)
Effective Shared Care Agreement (ESCA) Azathioprine (either alone or more usually in combination with corticosteroids and/or other drugs and procedures) ESCA: For the treatment of systemic lupus erythematosus
More informationSHARED CARE GUIDELINE FOR CICLOSPORIN IN DERMATOLOGY. 1. Aim/Purpose of this Guideline. 2. The Guidance
SHARED CARE GUIDELINE FOR CICLOSPORIN IN DERMATOLOGY 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration
More informationHydroxychloroquine (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,
More informationMETHOTREXATE (Adults)
Shared Care Guideline Methotrexate (Adults) Contents Introduction:... 1 Contraindications & Warnings:... 2 Interactions:... 3 Adverse Effects:... 3 Responsibilities of the specialist initiating treatment:...
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationDMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE
DMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE LIST OF DRUGS INCLUDED: ACITRETIN (Neotigason) ADALIMUMAB AMIODARONE AMISULPIRIDE ARIPRAZOLE AZATHIOPRINE CICLOSPORIN CYCLOPHOSPHAMIDE CLOZAPINE DENOSUMAB
More informationFACTSHEET CICLOSPORIN. Introduction. How does ciclosporin work? When is ciclosporin used?
Introduction Ciclosporin is a potent immunosuppressant drug that requires supervision by a specialised doctor such as a dermatologist. It was originally used to prevent organ rejection in transplant patients.
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationShared Care Guideline
Shared Care Guideline Ciclosporin (Neoral ) in inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of ciclosporin. Starting dose of 5-8mg/kg (in twice daily divided
More informationLeflunomide (Arava )
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP
ESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP Dermatology/ Haematology/ Gastroenterology/ Neurology/ Ophthalmology/ Respiratory/
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017 Author(s)/Originator(s): (please state author
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: TACROLIMUS Protocol number: CV 43
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: TACROLIMUS Protocol number: CV 43 Indications: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS.
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: CICLOSPORIN Protocol number: CV 06
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: CICLOSPORIN Protocol number: CV 06 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationTrust-wide Guideline
Trust-wide Guideline For Shared Care Guidelines for the Use of Leflunomide (Arava ) A guideline recommended for use In: East and North Herts NHS Trust (ENHT) East and North Herts PCT/ENHCCG By: Consultants
More informationTACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver disease
Oxford Gastroenterology Unit Shared Care Protocol & Information for GPs TACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Shared Care Guideline for Sulfasalazine in Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationDorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )
INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the
More informationSUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF)
SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF) Please refer to Chester Rheumatology shared care protocol for MMF and separate responsibilities document for full details. Responsibilities
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017 Author(s)/Originator(s): (please state author
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationSHARED CARE AGREEMENT: METHOTREXATE S/C
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) and BSR Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy (available at www.rheumatology.org.uk/resources/guidelines/bsr_guidelines.aspx
More informationSCG: For Transplant patients AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE
SCG: For Transplant patients The following guidelines are designed to provide information relating to tacrolimus and to outline the responsibilities of the primary and secondary care teams in the prescribing
More informationWORKING IN PARTNERSHIP WITH
WORKING IN PARTNERSHIP WITH Brighton and Hove Clinical Commissioning Group Crawley Clinical Commissioning Group Horsham and Mid Sussex Clinical Commissioning Group High Weald Lewes Havens Clinical Commissioning
More informationSOMATROPIN ( Genotropin, Humatrope, Norditropin,
Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationPRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis
PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Azathioprine and 6-Mercaptopurine for Chronic Inflammatory Bowel Disease Author(s)/Originator(s): (please state
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. Tivozanib. PROTOCOL REF: MPHATIVOUR (Version No: 1.
Systemic Anti Cancer Treatment Protocol Tivozanib PROTOCOL REF: MPHATIVOUR (Version No: 1.0) Approved for use in: Tivozanib is indicated for the first line treatment of advanced / metastatic renal cell
More informationLEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol
Oxfordshire Clinical Commissioning Group LEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol This protocol provides prescribing and monitoring guidance for leflunomide therapy.
More informationTacrolimus. Information for patients about using the drug Tacrolimus.
Tacrolimus Information for patients about using the drug Tacrolimus. Your consultant has recommended you start treatment with tacrolimus. This leaflet has been developed to provide you with additional
More informationMycophenolate Mofetil (MMF)
SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in
More informationEast Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions
East Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions This shared care agreement outlines the responsibilities for managing the prescribing
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: HYDROXYCHLOROQUINE INDICATION/S COVERED: active rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus Coastal West
More informationSHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation in Adults
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation
More informationBasingstoke,Winchester and Southampton District Prescribing Committee. Shared Care Guideline: Prograf (Tacrolimus)
Basingstoke,Winchester and Southampton District Prescribing Committee Shared Care Guideline: Prograf (Tacrolimus) Name of patient treated under this guideline: This shared care guideline has been produced
More informationBasingstoke,Winchester and Southampton District Prescribing Committee. Shared Care Guideline: Sirolimus
Basingstoke,Winchester and Southampton District Prescribing Committee Shared Care Guideline: Sirolimus Name of patient treated under this guideline: This shared care guideline has been produced to support
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationShared Care Guidelines. In partnership with Acute Trust & PCTs. SIROLIMUS In renal transplant. August 2016
Shared Care Guidelines In partnership with Acute Trust & PCTs SIROLIMUS In renal transplant August 2016 Page 0 of 12 Table of Contents Introduction 2 Licensing 2 Referral 2 Initiation and maintenance of
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION
More informationIf your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment.
If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment. What is tacrolimus? Patient Information Drugs for Inflammatory Bowel Disease Tacrolimus
More informationThis guideline is under review. Please continue to use this version until the review has been completed
This guideline is under review. Please continue to use this version until the review has been completed SHARED CARE PRESCRIBING GUIDELINE Continuation of Advagraf (tacrolimus modified release {MR}) for
More informationShared care guidelines for azathioprine in adults. General principles. Presentation/Dose/Administration Oral: 25mg and 50mg tablets
Shared care guidelines for azathioprine in adults General principles This agreement outlines suggested ways in which the responsibilities for managing the prescribing of the drug treatment and clinical
More informationPrescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...
More informationShared Care Guideline. Prescribing and Monitoring of oral METHOTREXATE in adults Licensed and off-label indications
North Central London Joint Formulary Committee Shared Care Guideline Prescribing and Monitoring of oral METHOTREXATE in adults Licensed and off-label indications Dear GP, Progressing to a stable, optimal
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Oral Methotrexate for Rheumatological Conditions Author(s)/Originator(s): (please state author name and department)
More informationVemurafenib (Zelboraf ) BRAF V600 mutation positive Metastatic Melanoma
Vemurafenib (Zelboraf ) BRAF V600 mutation positive Metastatic Melanoma Background: Vemurafenib has been approved by NICE for the treatment of BRAF V600 mutation positive unresectable or metastatic melanoma.
More informationWeekly oral and subcutaneous methotrexate
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationShared Care Guideline
Shared Care Guideline Mercaptopurine inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of mercaptopurine. Dosing: 25mg daily for two weeks, then 1-1.5mg/kg
More informationMalignant disease. Chapter 8 TABLE OF CONTENTS. BNF for Pre-reg Humza Yusuf Ibrahim
Chapter 8 Malignant disease TABLE OF CONTENTS Table of Contents... 1 1 Immune system... 2 1.1 Antiproliferative immunosuppressants... 2 1.1.1 Azathioprine... 2 1.1.2 Mycophenolate... 2 1.2 Ciclosporin
More informationDRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.
`Shared Care Guidelines DRUG: Introduction Inhaled antibiotics (Adults and Paediatrics) in Cystic Fibrosis. EXISTING ESTABLISHED PATIENTS ONLY Colistimethate (Colomycin, Promixin ) Tobramycin (Tobi Bramitob
More informationIBRUTINIB (IMBRUVICA ) for Chronic Lymphocytic Leukaemia. and Mantel Cell Lymphoma
DRUG ADMINISTRATION SCHEDULE Indication Cycle Length Drug Daily Dose Route Schedule Chronic Lymphocytic Leukaemia Continuous Ibrutinib 420mg (three capsules) Oral ONCE daily Mantel Cell Lymphoma Continuous
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: AZATHIOPRINE INDICATION/S COVERED: FOR RHEUMATOLOGY AND DERMATOLOGY
WORKING IN PARTNERSHIP WITH Coastal West Sussex Traffic Light system classification: Amber N.B. The eligibility criteria included here apply to new patients commencing treatment under this agreement &
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationWeekly oral and subcutaneous methotrexate
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationV4.1 Amendment to hydroxychloroquine ophthalmology monitoring made. Agreed by Camden Medicines Management Committee: October 2017 August 2017
North Central London Joint Formulary Committee Quick Reference Guide for Primary Care Prescribers Monitoring Disease Modifying Anti-Rheumatic Drugs (DMARDs) Azathioprine, Mercaptopurine, Sulfasalazine,
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationShared Care Guideline: Leflunomide
Basingstoke, Winchester & Southampton District Prescribing Committee Shared Care Guideline: Leflunomide Name of patient treated under this guideline: This shared care guideline has been produced to support
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationWestern Locality Shared care Information ~ Methotrexate, Rheumatology April 2013
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationShared Care Guideline Metolazone for fluid management in CKD (Adults)
Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility
More informationShared Care Guideline for Ranolazine in the Management of Stable Angina Pectoris
Shared Care Guideline for Ranolazine in the Management of Stable Angina Pectoris Introduction Indication/Licensing information Ranolazine (Ranexa), as recommended by NICE, is indicated in adults as add-on
More informationCardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE
Cardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE Drug: RILUZOLE Protocol number: CV 39 Indication: AMYOTROPHIC LATERAL SCLEROSIS (ALS) General Guidance
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More information